ReviewViruses2026
Bacteriophages as Food Biocontrol Agents: A One Health Framework for Manufacturing Quality, Regulatory Governance, and Ethical Stewardship-A Narrative Review.
Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bacteriophages as post-harvest biocontrol agents againstFrontiers in nutrition · 2026Pooled it
- Biocontrol of Staphylococcus aureus in dairy products using lytic bacteriophage UHP46: efficacy in milk, cheese, and yogurt.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Regulatory Harmonization Needs for Farm-to-Fork Bacteriophage Applications in South American Food Systems.Foods (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionBacteriophages are emerging as viable food safety tools, yet their global implementation is hindered by regulatory fragmentation and a lack of harmonized data standards. This review addresses the gap between scientific maturity and governance readiness by evaluating manufacturing quality, safety requirements, and international oversight frameworks.
methodsA narrative review was conducted through a structured search of databases including PubMed, Scopus, Web of Science, and Google Scholar (up to December 2025). We analyzed scientific research and publicly available regulatory documents from agencies such as the FDA, EFSA, USDA, Health Canada, and FSANZ to identify authorization routes and manufacturing standards.
resultsCommercial phage products are primarily approved as processing aids in jurisdictions like the United States, Canada, and Australia/New Zealand. We identified convergent technical requirements across these regions, including genomic integrity (absence of toxins and antimicrobial resistance genes), purity, potency, and matrix-validated efficacy. However, significant gaps remain in unified terminology, environmental risk assessment, and post-market monitoring for resistance emergence.
conclusionsTo facilitate global adoption, a One Health-oriented governance cycle is proposed. This includes establishing interoperable phage seed banks, standardized dossier formats, and adaptive lifecycle controls (phagovigilance) to ensure long-term efficacy and public trust.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.